Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 17/20 | 0.61 |
| ▸ | CDK7 | P50613 | 13/20 | 0.55 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | CLK3 | P49761 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | ITK | Q08881 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058923 | 0.90 | CHEK1 (0.74) | CHEK1CDK7CLK2CLK3DYRK1A | |
| SCHEMBL5061569 | 0.85 | CHEK1 (0.74) | CHEK1CDK7CLK2CLK3DYRK1A | |
| SCHEMBL5051865 | 0.84 | CHEK1 (0.84) | CHEK1CDK7 | |
| SCHEMBL5051852 | 0.83 | CHEK1 (0.65) | CHEK1CDK7CLK2CLK3DYRK1A | |
| SCHEMBL5054039 | 0.81 | CHEK1 (0.59) | CHEK1CDK7CLK2CLK3DYRK1A | |
| SCHEMBL5053998 | 0.81 | CHEK1 (0.61) | CHEK1CDK7CLK2CLK3DYRK1A | |
| SCHEMBL5051909 | 0.80 | CHEK1 (0.58) | CHEK1CDK7 | |
| SCHEMBL5054055 | 0.79 | CHEK1 (0.84) | CHEK1CDK7 | |
| SCHEMBL5054025 | 0.79 | FLT3 (0.58) | CHEK1CDK7 | |
| SCHEMBL5051817 | 0.77 | CHEK1 (0.47) | CHEK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004259-A1 | Inhibitors of Checkpoint Kinases | MERCK & CO., INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004259-A1 | Inhibitors of Checkpoint Kinases | MERCK & CO., INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004259-A1 | Inhibitors of Checkpoint Kinases | MERCK & CO., INC. | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004259-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, BUB1B | CHEK1 1/4885CDK7 43/4885CLK2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.